EMRICASAN

EMRICASAN

Biochem/physiol Actions

Emricasan, formerly known as IDN-6556, in combination with birinapan is used to treat acute myeloid leukemia (AML). This small molecule irreversible inhibitor is under clinical investigation to reduce hepatic injury and liver fibrosis.

Emricasan is an antiapoptotic pan-caspase inhibitor. It has been in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) with advanced fibrosis (scarring) and cirrhosis. Emricasan has also been shown to protect infected astrocytes from ZIKV-induced cell death.

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3575995 EMRICASAN white to beige SIGMA-ALDRICH −20°C DMSO: 2 mg/mL, clear
£594.75 (exc VAT) per 25MG
-
+
3575996 EMRICASAN white to beige SIGMA-ALDRICH −20°C DMSO: 2 mg/mL, clear
£174.11 (exc VAT) per 5MG
-
+